

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG505 Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Scoping

1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they?

Congenital heart defects are more common in children with genetic conditions including Down's syndrome, Noonan syndrome and Turner's syndrome.

People with congenital heart disease themselves are at increased risk of having a child with the condition, between 2.5 and 18% for mothers and 1.5 and 3.0% for fathers. Parents of children with congenital heart disease have around a 1 in 50 chance of having another child with the condition. Other risk factors include maternal diabetes, flu during pregnancy, foetal alcohol syndrome, contracting rubella or exposure to organic solvents.

The device is restricted to infants weighing less than 6 kg and with congenital heart disease. In the Equality Act 2010, a physical or mental impairment in a child under the age of 6 is treated as having a substantial and long term adverse effect on the ability of that child to carry out normal day to day activities. It is therefore likely they would be classed as disabled under the Act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified?

It was considered that these issues would not have an impact on the assessment of the procedure.

3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality issues?

No

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Not applicable.

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?

No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligation to promote equality?

Not applicable

6. Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where?

Not applicable

Final interventional procedures document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

Not applicable

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

4. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?

Not applicable

Approved by Programme Director

Date: 01.10.2014